Post-Transplant Cyclophosphamide (PTCy) for GVHD Prophylaxis in HLA- Matched Related Donor HSCT in Pediatric and Adult Patients. Evidence of Real-Life Outcomes from a Latin American Transplant Center.
Puntos clave
evidence supports the effectiveness of cyclophosphamide for GVHD prophylaxis in both pediatric and adult patients, enhancing transplant success.
outcomes show improved GVHD rates post-transplant through the use of cyclophosphamide as a preventive measure.
the observational analysis focused on a Latin American transplant center, providing insights into regional practices and outcomes.
this approach may highlight the necessity for broader guidelines in GVHD management across different demographics.
Post-Transplant Cyclophosphamide (PTCy) for GVHD Prophylaxis in HLA- Matched Related Donor HSCT in Pediatric and Adult Patients. Evidence of Real-Life Outcomes from a Latin American Transplant Center. | Synapse